Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | yo12076 | SC / RL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y012076 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y007176 | — |
No additional AE; report administration of VARIVAX and PROQUAD today; This spontaneous report was received from a medical assistant (MA) and refers to a(n) 1-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 03-Apr-2025 (reported as today), the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), lot #Y007176, expiration date was reported as 26-Apr-2026 but was established as 04-Apr-2026 upon internal validation (strength, dose, route of administration and anatomical location were not provided) and Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), lot #Y012076, expiration date was reported as 26-Jan-2026 but was established as 05-Jan-2026 upon internal validation (strength, dose, route of administration and anatomical location were not provided), administered for prophylaxis (Inappropriate schedule of vaccine administered). The vaccines were reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot#, expiry date and dosage information were not provided). Patient was not experiencing any symptoms. Confirmed no additional information. No additional AE (No adverse event).
Sterile diluent